BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:Driven by a surging pipeline\, the MASH therapeutic landscape 
 is radically transforming as more drugs reach clinical trials. While Madr
 igal's Rezdiffra marked a groundbreaking first approval\, it also highlig
 hted the vast scope for further\, more comprehensive\, patient-centered s
 olutions. This is a pivotal moment to unlock unparalleled potential in co
 nquering this widespread disease.\n\nThe 9th MASH Drug Development Summit
  is the essential forum for pharmaceutical giants and innovative biotechs
  dedicated to accelerating efficacious therapies for diverse patient popu
 lations. This year\, we're diving deep into the game-changing potential o
 f novel mechanisms of action\, advanced biomarker integration\, and strat
 egic combination and sequential therapy regimens. Hear from titans such a
 s Eli Lilly\, AstraZeneca\, Pfizer\, and Takeda\, alongside innovative bi
 otechs such as Madrigal\, Akero Therapeutics\, 89 Bio\, and more. Learn o
 f the groundbreaking research and strategies focused on effective treatme
 nts through varied mechanisms and cell-targeting\, accurate non-invasive 
 biomarkers\, patient-centered trial designs\, and the profound potential 
 of GLP-1s. The pressure is on to develop best-in-class treatments that tr
 ansform patient lives.\n\nDon't miss this pivotal opportunity to network 
 with 60+ leading MASH scientists and drug development experts\, forge cru
 cial collaborations\, and be part of the solution!\n\nURLs:Tickets: https
 ://go.evvnt.com/3126388-2?pid=185Brochure: https://go.evvnt.com/3126388-3
 ?pid=185\n\nTime: 8:00 AM - 5:00 PM\n\nPrices:Drug Developer Pricing - 3 
 Day Pass (Conference + Pre-Conference Focus Day): USD 4197.00\,Drug Devel
 oper Pricing - 2 Day Pass (Conference Only): USD 2999.00\,Academic and No
 t-for-Profit Pricing - 3 Day Pass (Conference + Pre-Conference Focus Day)
 : USD 3597.00\,Academic Pricing - 2 Day Pass (Conference Only): USD 2599.
 00\,Solution Provider Pricing - 3 Day Pass (Conference + Pre-Conference F
 ocus Day): USD 5097.00\,Solution Provider Pricing - 2 Day Pass (Conferenc
 e Only): USD 3699.00\n\nSpeakers: Belle Van Rosmalen\, Director\, Medical
  Development\, Incretin Outcomes\, Eli Lilly\, Cynthia Arbeeny\, Chief Sc
 ientific Officer\, Mitotherapeutix\, Cynthia Lebaupin\, Senior Scientist\
 , Pfizer\, Girish Rao\, Executive Director\, Clinical Design-Cardiometabo
 lic Health\, Clinical Design Delivery and Analytics\, Eli Lilly\, Hank Ma
 nsbach\, Chief Medical Officer\, 89 Bio\, Jen-Chieh Chuang\, Director\, T
 ranslational Biomarker Lead\, Liver diseases\, Takeda Pharmaceuticals\, J
 ulio Gutierrez\, Director\, Medical\, Altimmune\, Kavita Juneja\, Senior 
 Director and Head of Metabolic Therapeutic Development\, Corcept Therapeu
 tics\, Kevin Hart\, Scientific Director\, Pfizer\, Kristin Fiorino\, Dire
 ctor - Medical\, AstraZeneca\, Marie O'Farrell\, Senior Vice President\, 
 Research and Development\, Sagimet Biosciences\, Oliver Yoa-Pu Hu\, Scien
 tific Board Member\, Sinew Pharma\, Patrice Mimche\, Associate Professor\
 , Indiana University\, Rebecca Taub\, Chief Executive Officer\, Madrigal\
 , Remi Laberge\, Co-Founder and Chief Technology Officer\, Arda Therapeut
 ics\, Reshma Shringapure\, Vice President\, Clinical Research Medical Aff
 airs\, Akero Therapeutics\, Saheli Chowdhury\, Postdoctoral Researcher\, 
 Columbia University\, Sharon Jaycox\, Director\, Fatty Liver Disease\, Gl
 obal Liver Institute\, Stanley Watowich\, Founder and Chief Executive Off
 icer\, Ridgeline Therapeutics\, Wen-Wei Tsai\, Director\, Sagimet Bioscie
 nces\, Winston Dunn\, Associate Professor\, University of Kansas Medical 
 Center\, Zoltan Derdak\, Medical Director\, Early Clinical Development\, 
 Takeda Pharmaceuticals\n
DTEND:20251001T170000
DTSTAMP:20260512T225910Z
DTSTART:20250929T080000
LOCATION:Hyatt Regency Boston / Cambridge\, 575\, Memorial Drive\, Cambrid
 ge\, Massachusetts\, 02139\,
SEQUENCE:0
SUMMARY:Driven by a surging pipeline\, the MASH therapeutic landscape is r
 adically transforming as more drugs reach clinical trials. While Madrigal
 's Rezdif...
UID:22f537ee-001f-41ba-ae23-0564fb24d478
END:VEVENT
END:VCALENDAR